{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T14:29:30Z","timestamp":1795271370750,"version":"4.10.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T00:00:00Z","timestamp":1451260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/npp.2015.367","type":"journal-article","created":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T07:00:58Z","timestamp":1451286058000},"page":"1974-1982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":195,"title":["Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis"],"prefix":"10.1038","volume":"41","author":[{"given":"Margaret","family":"Haney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanna","family":"Babalonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-2332","authenticated-orcid":false,"given":"Ziva D","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillinder","family":"Bedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"McRae-Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R","family":"Lofwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sparenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,28]]},"reference":[{"key":"BFnpp2015367_CR1","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/BF02085029","volume":"37","author":"S Agurell","year":"1981","unstructured":"Agurell S, Carlsson S, Lindgren J, Ohlsson A, Gillespie H, Hollister L (1981). Interactions of \u039411-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographywith cannabinol and cannabidiol following oral administration in man. Assay of cannab. Experientia 37: 1090\u20131092.","journal-title":"Experientia"},{"key":"BFnpp2015367_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0031-6997(25)06861-9","volume":"38","author":"S Agurell","year":"1986","unstructured":"Agurell S, Haldin M, Lindgren J, Ohlsson A, Widman M, Gillespie H et al (1986). Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38: 21\u201343.","journal-title":"Pharmacol Rev"},{"key":"BFnpp2015367_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/clpt.1980.139","volume":"28","author":"NL Benowitz","year":"1980","unstructured":"Benowitz NL, Nguyen T, Jones RT, Herning R, Bachman J (1980). Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 28: 115\u2013120.","journal-title":"Clin Pharmacol Ther"},{"key":"BFnpp2015367_CR4","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"M Bergamaschi","year":"2011","unstructured":"Bergamaschi M, Queiroz R, Chagas M, Oliveira D, Martinis B, Kapczinski F et al (2011a). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients. Neuropsychopharmacology 36: 1219\u20131226.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015367_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"M Bergamaschi","year":"2011","unstructured":"Bergamaschi M, Queiroz R, Zuardi A, Crippa J (2011b). safety and side effects of cannabidiol, a cannabis sativa constituent. Curr Drug Safety 6: 237\u2013249.","journal-title":"Curr Drug Safety"},{"key":"BFnpp2015367_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archgenpsychiatry.2009.17","volume":"66","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O\u2019Carroll C et al (2009). Modulation of Mediotemporal and Ventrostriatal Function in Humans by \u03949-Tetrahydrocannabinol. Arch Gen Psychiatry 66: 442\u2013442.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2015367_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T et al (2010). Opposite effects of \u0394-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764\u2013774.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015367_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.biopsych.2008.05.011","volume":"64","author":"S Borgwardt","year":"2008","unstructured":"Borgwardt S, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML et al (2008). neural basis of \u0394-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64: 966\u2013973.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2015367_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0306-4603(89)90017-8","volume":"14","author":"LD Chait","year":"1989","unstructured":"Chait LD, Pierri J (1989). Some physical characteristics of NIDA marijuana cigarettes. Addict Behav 14: 61\u201367.","journal-title":"Addict Behav"},{"key":"BFnpp2015367_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R et al (1991). Controlled clinical trial of cannabidiol in Huntington\u2019s Disease. Pharmacol Biochem Behav 40: 701\u2013708.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFnpp2015367_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1369-1600.2007.00095.x","volume":"13","author":"ZD Cooper","year":"2008","unstructured":"Cooper ZD, Haney M (2008). Cannabis reinforcement and dependence: Role of the cannabinoid CB1 receptor. Addict Biol 13: 188\u2013195.","journal-title":"Addict Biol"},{"key":"BFnpp2015367_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"J Crippa","year":"2011","unstructured":"Crippa J, Derenusson GN, Ferrari TB, Wichert-Ana L, Dura F, Marti N-Santos RO et al (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder-a preliminary report. J Psychopharmacol 25: 121\u2013130.","journal-title":"J Psychopharmacol"},{"key":"BFnpp2015367_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.npp.1300340","volume":"29","author":"JA Crippa","year":"2004","unstructured":"Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L et al (2004). Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow. Neuropsychopharmacology 29: 417\u2013426.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015367_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/cpt1976193300","volume":"19","author":"WS Dalton","year":"1976","unstructured":"Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976). Influence of cannabidiol on delat-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 19: 300\u2013309.","journal-title":"Clin Pharmacol Ther"},{"key":"BFnpp2015367_CR15","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","volume":"33","author":"DC D'Souza","year":"2008","unstructured":"D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T et al (2008). Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33: 2505\u20132516.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015367_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/acprof:oso\/9780199662685.003.0001","volume-title":"Handbook of Cannabis","author":"M ElSohly","year":"2014","unstructured":"ElSohly M, Gul W (2014) Constituents of cannabis sativa. In: Pertwee Roger G (ed). Handbook of Cannabis. Oxford University Press: New York, NY, USA, pp 3\u201322."},{"key":"BFnpp2015367_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00213-002-1349-y","volume":"165","author":"M ElSohly","year":"2003","unstructured":"ElSohly M, Wachtel S, Wit H (2003). Cannabis versus THC: response to Russo and McPartland. Psychopharmacology 165: 433\u2013434.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015367_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S et al (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacology 27: 19\u201327.","journal-title":"J Psychopharmacology"},{"key":"BFnpp2015367_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0376-8716(87)90079-2","volume":"20","author":"RW Foltin","year":"1987","unstructured":"Foltin RW, Brady JV, Fischman MW, Emurian CS, Dominitz J (1987). Effects of smoked cannabis on social interaction in small groups. Drug Alcohol Depend 20: 87\u201393.","journal-title":"Drug Alcohol Depend"},{"key":"BFnpp2015367_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","volume":"66","author":"P Fusar-Poli","year":"2009","unstructured":"Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R et al (2009). Distinct effects of \u03949-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66: 95\u2013105.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2015367_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2174\/156800705774322111","volume":"4","author":"F Grotenhermen","year":"2005","unstructured":"Grotenhermen F (2005). Cannabinoids. Curr Drug Targets CNS Neurol Disord 4: 507\u2013530.","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"BFnpp2015367_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/sj.npp.1300310","volume":"29","author":"M Haney","year":"2004","unstructured":"Haney M, Hart CL, Vosburg SK, Nasser J, Bennet A, Zubaran C et al (2004). Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29: 158\u2013170.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015367_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","volume":"199","author":"M Haney","year":"2008","unstructured":"Haney M, Spealman R (2008). Controversies in translational research: drug self-administration. Psychopharmacology 199: 403\u2013419.","journal-title":"Psychopharmacology"},{"key":"BFnpp2015367_CR24","unstructured":"Hardwick S, King LA (2008) Home Office Cannabis Potency Study. Home Office Scientific Development Branch: St Albans. Report."},{"key":"BFnpp2015367_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0893-133X(01)00273-1","volume":"25","author":"C Hart","year":"2001","unstructured":"Hart C, Van Gorp W, Haney M, Foltin R, Fischman M (2001). effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25: 757\u2013765.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015367_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1192\/bjp.bp.110.081380","volume":"197","author":"C Henquet","year":"2010","unstructured":"Henquet C, Kuepper R (2010). Does cannabidiol protect against the negative effects of THC? Br J Psychiatry 197: 259\u2013260.","journal-title":"Br J Psychiatry"},{"key":"BFnpp2015367_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","volume":"25","author":"C Hindocha","year":"2015","unstructured":"Hindocha C, Freeman T, Schafer G, Gardener C, Das R, Morgan C et al (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 25: 325\u2013334.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"BFnpp2015367_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF01059266","volume":"9","author":"C. Anthony Hunt","year":"1981","unstructured":"Hunt C, Jones R, Herning R, Bachman J (1981). Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinetics Biopharmaceutics 245\u2013260.","journal-title":"Journal of Pharmacokinetics and Biopharmaceutics"},{"key":"BFnpp2015367_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/00008877-200509000-00023","volume":"16","author":"A Ilan","year":"2005","unstructured":"Ilan A, Gevins A, Coleman M, Elsohly M, Wit H (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 16: 487\u2013496.","journal-title":"Behav Pharmacol"},{"key":"BFnpp2015367_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","volume":"30","author":"A Izzo","year":"2009","unstructured":"Izzo A, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009). non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515\u2013527.","journal-title":"Trends Pharmacol Sci"},{"key":"BFnpp2015367_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.schres.2007.08.015","volume":"97","author":"G Juckel","year":"2007","unstructured":"Juckel G, Roser P, Nadulski T, Stadelmann A, Gallinat J (2007). Acute effects of \u03949-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 97: 109\u2013117.","journal-title":"Schizophr Res"},{"key":"BFnpp2015367_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","volume":"28","author":"I Karniol","year":"1974","unstructured":"Karniol I, Shirakawa I, Kasinski N, Pfeferman A, Carlini E (1974). Cannabidiol interferes with the effects of \u03949-tetrahydrocannabinol in man. Eur J Pharmacol 28: 172\u2013177.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2015367_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1373\/clinchem.2010.152439","volume":"57","author":"E Karschner","year":"2011","unstructured":"Karschner E, Darwin W, Goodwin R, Wright S, Huestis M (2011a). Plasma cannabinoid pharmacokinetics following controlled oral 9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 57: 66\u201375.","journal-title":"Clin Chem"},{"key":"BFnpp2015367_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/clpt.2010.318","volume":"89","author":"E Karschner","year":"2011","unstructured":"Karschner E, Darwin W, Mcmahon R, Liu F, Wright S, Goodwin R et al (2011b). Subjective and physiological effects after controlled sativex and oral thc administration. Clin Pharmacol Ther Clin Pharmacol Ther 89: 400\u2013407.","journal-title":"Clin Pharmacol Ther Clin Pharmacol Ther"},{"key":"BFnpp2015367_CR35","doi-asserted-by":"publisher","first-page":"E94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C et al (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2: E94.","journal-title":"Transl Psychiatry"},{"key":"BFnpp2015367_CR36","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/bph.12400","volume":"170","author":"R Mechoulam","year":"2013","unstructured":"Mechoulam R, Parker L (2013). Towards a better cannabis drug. Br J Pharmacol 170: 1363\u20131364.","journal-title":"Br J Pharmacol"},{"key":"BFnpp2015367_CR37","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","volume":"42","author":"R Mechoulam","year":"2002","unstructured":"Mechoulam R, Parker L, Gallily R (2002). cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42: 11S\u201319S.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"BFnpp2015367_CR38","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/npp.2010.58","volume":"35","author":"Celia JA Morgan","year":"2010","unstructured":"Morgan C, Freeman T, Schafer G, Curran H (2010). Cannabidiol attenuates the appetitive effects of \u03949-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 1879\u20131885.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015367_CR39","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3389\/fpsyt.2013.00130","volume":"4","author":"RJ Niesink","year":"2013","unstructured":"Niesink RJ, van Laar MW (2013). Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry 4: 130.","journal-title":"Front Psychiatry"},{"key":"BFnpp2015367_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR et al (2010). International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588\u2013631.","journal-title":"Pharmacol Rev"},{"key":"BFnpp2015367_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1556-4029.2007.00603.x","volume":"53","author":"DJ Potter","year":"2008","unstructured":"Potter DJ, Peter C, Brown MB (2008). Potency of D9\u2013THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53: 90\u201394.","journal-title":"J Forensic Sci"},{"key":"BFnpp2015367_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00406-009-0868-5","volume":"259","author":"P Roser","year":"2009","unstructured":"Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann A (2009). Psychomotor performance in relation to acute oral administration of \u03949-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. Eur Arch Psychiatry Clin Neurosci 259: 284\u2013292.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFnpp2015367_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","volume":"66","author":"EB Russo","year":"2006","unstructured":"Russo EB, Guy GW (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234\u2013246.","journal-title":"Med Hypotheses"},{"key":"BFnpp2015367_CR44","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"E Ryberg","year":"2007","unstructured":"Ryberg E, Larsson N, Sj\u00f6gren S, Hjorth S, Hermansson N, Leonova J et al (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092\u20131101.","journal-title":"Br J Pharmacol"},{"key":"BFnpp2015367_CR45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hup.1196","volume":"26","author":"K Schoedel","year":"2011","unstructured":"Schoedel K, Chen N, Hilliard A, White L, Stott C, Russo E et al (2011). A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 26: 224\u2013236.","journal-title":"Hum Psychopharmacol"},{"key":"BFnpp2015367_CR46","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00228-012-1441-0","volume":"69","author":"CG Stott","year":"2013","unstructured":"Stott CG, White L, Wright S, Wilbraham D, Guy GW (2013). A phase I study to assess the single and multiple dose pharmacokinetics of THC\/CBD oromucosal spray. Eur J Clin Pharmacol 69: 1135\u20131147.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFnpp2015367_CR47","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Behavioral Health Statistics and Quality (2014). Treatment Episode Data Set (TEDS) 2002-2012 National Admissions to Substance Abuse Treatment Services. BHSIS Series S-71, HHS Publication No. (SMA) 14\u20134850."},{"key":"BFnpp2015367_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npp.2010.171","volume":"36","author":"TT Winton-Brown","year":"2011","unstructured":"Winton-Brown TT, Allen P, Bhattacharyya S, Borgwardt SJ, Fusar-Poli P, Crippa JA et al (2011). Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an fmri study. Neuropsychopharmacology 36: 1\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2015367_CR49","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/bph.12199","volume":"170","author":"MJ Wright Jr","year":"2013","unstructured":"Wright MJ Jr, Vandewater SA, Taffe MA (2013). Cannabidiol attenuates deficits of visuospatial associative memory induced by \u0394(9) tetrahydrocannabinol. Br J Pharmacol 170: 1365\u20131373.","journal-title":"Br J Pharmacol"},{"key":"BFnpp2015367_CR50","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/ph5050529","volume":"5","author":"S Zhornitsky","year":"2012","unstructured":"Zhornitsky S, Potvin S (2012). Cannabidiol in humans\u2014the quest for therapeutic targets. Pharmaceuticals (Basel) 5: 529\u2013552.","journal-title":"Pharmaceuticals (Basel)"},{"key":"BFnpp2015367_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","volume":"7","author":"A Zuardi","year":"1993","unstructured":"Zuardi A, Cosme R, Graeff F, Guimar\u00e3es F (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychoparmacol 7: 82\u201388.","journal-title":"J Psychoparmacol"},{"key":"BFnpp2015367_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","volume":"76","author":"AW Zuardi","year":"1982","unstructured":"Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by D9-THC in normal subjects. Psychopharmacology 76: 245\u2013250.","journal-title":"Psychopharmacology"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2015367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2015367","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2015367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T19:09:53Z","timestamp":1748718593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2015367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,28]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFnpp2015367"],"URL":"https:\/\/doi.org\/10.1038\/npp.2015.367","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726047665.793542280","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,28]]},"assertion":[{"value":"29 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}